What You Need To Know About The Lakefront Biotherapeutics NV (AMS:LKFT) Analyst Downgrade Today
Market forces rained on the parade of Lakefront Biotherapeutics NV (AMS:LKFT) shareholders today, when the analysts downgraded their forecasts for this year. This report focused on revenue estimates, and it looks as though the consensus view of the business has become substantially more conservative.
After the downgrade, the consensus from Lakefront Biotherapeutics' nine analysts is for revenues of €117m in 2026, which would reflect a sizeable 89% decline in sales compared to the last year of performance. Before the latest update, the analysts were foreseeing €150m of revenue in 2026. It looks like forecasts have become a fair bit less optimistic on Lakefront Biotherapeutics, given the pretty serious reduction to revenue estimates.
Check out our latest analysis for Lakefront Biotherapeutics
Another way we can view these estimates is in the context of the bigger picture, such as how the forecasts stack up against past performance, and whether forecasts are more or less bullish relative to other companies in the industry. These estimates imply that sales are expected to slow, with a forecast annualised revenue decline of 95% by the end of 2026. This indicates a significant reduction from annual growth of 7.8% over the last five years. By contrast, our data suggests that other companies (with analyst coverage) in the same industry are forecast to see their revenue grow 15% annually for the foreseeable future. So although its revenues are forecast to shrink, this cloud does not come with a silver lining - Lakefront Biotherapeutics is expected to lag the wider industry.
The Bottom Line
The most important thing to take away is that analysts cut their revenue estimates for this year. They're also anticipating slower revenue growth than the wider market. Overall, given the drastic downgrade to this year's forecasts, we'd be feeling a little more wary of Lakefront Biotherapeutics going forwards.
Of course, there's always more to the story. At least one of Lakefront Biotherapeutics' nine analysts has provided estimates out to 2028, which can be seen for free on our platform here.
Of course, seeing company management invest large sums of money in a stock can be just as useful as knowing whether analysts are downgrading their estimates. So you may also wish to search this free list of stocks with high insider ownership.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.